Contacts

Management

Claudio Bordignon MD
Chairman

Riccardo Palmisano MD
CEO

Luca Alberici
Business Development

Germano Carganico
Executive Director, Strategic Affairs

Cynthia Giuliani
Human Resources & General Services

Marco Manoni
Safety and Facilities

Silvia Pisante
Legal Affairs & Corporate Governance

Andrea Quaglino
Administration, Finance and Control

Laura Villa
Investor Relations & Communication

Tiziano Andreoli 
Information Technology

Antonio Lambiase
Clinical Development

Catia Traversari
Research

- - -

Claudio Bordignon MD
Chairman 

Claudio Bordignon, MolMed’s founder, has an established international reputation as a pioneer in gene and cell therapy, and is widely known for the clinical validation of several successful gene therapy protocols for both genetic and acquired disorders, including leukaemias and other malignancies. He is the author of more than 150 publications and inventor of several patents, that represent crucial components of the company’s core technologies. He is Professor of Haematology at the University Vita-Salute San Raffaele Medical School, and Director of the Clinical Training Program in Haematology. In 2005, he was appointed by the EU Commission as one of the 22 eminent members of the Scientific Council of the European Research Council (ERC), today today the most important European funding Agency for innovative research.
He served as Scientific Director of the San Raffaele Scientific Institute (1998-2006) and held positions as Director of Haematology, Head of the Gene Therapy and Bone Marrow Transplantation Program. Claudio Bordignon received his MD from the School of Medicine of the University of Milan, and completed his medical and science training during eight years spent in several of the most prestigious U.S. institutions, including four years at Memorial Sloan Kettering Cancer Center (New York).

 

Riccardo Palmisano
CEO

Dr. Riccardo Palmisano, CEO at MolMed since December 2015, graduated in Medicine in 1985 at Parma University. His career in the Italian pharmaceutical industry started in 1986 at Farmitalia Carlo Erba (1986), he then moved on to Gruppo Menarini (1988) where he contributed to the development and internationalisation of the first Italian pharmaceutical Group, becoming Director of the Pharmaceutical Division Italy in 1993 and General Manager at Lusofarmaco in 1995. His career in multinational companies started in 2000: he set up the Italian branch of Shire Pharmaceutical (2000), then he was appointed Vice President Commercial Retail Market in GlaxoSmithKline Verona (2003) and, lastly, Vice President & General Manager Italy at Genzyme (2005), a U.S. biotech company specialized in research and development of orphan drugs for rare diseases. After the acquisition of Genzyme by Sanofi he was appointed Director of Business Strategy and Development at Sanofi Italia (2012-2013).
During his career, he successfully launched a large number of important products in many therapeutic areas, in both retail and hospital markets, participated and supported several international projects, and successfully negotiated pricing and reimbursement for several innovative drugs with the Italian Authorities. In 2008, he joined Assobiotec, the trade association part of Federchimica, that brings together Italian biotech companies, becoming Vice President, responsible for biotech pharma and health, in 2010. In 2016, was appointed President of Assobiotec.

 

Luca Alberici, PhD, MBA
Business Development 

Luca Alberici is Director of Business Development since April 2015. He joined MolMed in 2006 and worked with growing responsibilities in R&D, contributing to the development of the Company’s “core” products and scouting and validation of potential drug candidates to enrich the portfolio. After a Master in Business Administration, he joined Bain & Company, a leading management consulting firm, where he was involved in strategic business planning, portfolio effectiveness, organization and process reengineering, due diligence and post-merger integration in healthcare and consumer good practices. Luca holds a Master degree in Medical, Molecular and Cellular Biotechnology from Vita-Salute San Raffaele University, a PhD in Cellular and Molecular Biology from the same institution and a Master In Business Administration from SDA Bocconi Milan.

 

Germano Carganico
Executive Director, Strategic Affairs

Germano Carganico has more than 30 years of experience in R&D, regulatory affairs and company management, gained in pharmaceutical and biotech companies, such as Farmitalia Carlo Erba, Menarini and Axxam. He has successfully managed the international registration of several new pharmaceutical products and has been founding partner of important leading consulting companies in the field of life sciences, namely Pharma Quality Europe, Regulatory Pharma Net and the non profit company Rare Partners.
In January 2011 he joined MolMed's management, where he held the position of General Manager, R&D and Operations until March 2015.
In the 5 years prior to his entry in MolMed, he served as General Manager of Toscana Life Sciences foundation and has taught Business Development at the University of Siena.
Germano Carganico holds a degree in Chemistry, obtained from the University of Milan in 1977.
.

Cynthia Giuliani
Human Resources & General Services

Cynthia Marina Giuliani joined MolMed as our director of human resources in February 2008.  She has 20 years experience in human resources, gained in multinational and biotech companies such as Roche and Liebert Hiross, and most recently in BioXell.
From 1988 to 1997 she worked for Roche in numerous human resources related functions. From 1998 to 2000 she worked as a consultant to a variety of companies. From 2000 to 2002 she worked for Liebert HIROSS S.p.A as that company’s European development manager, focusing on the recruitment and continuing education of personnel. Finally, before joining MolMed, Cynthia Giuliani worked for Bioxell, another biotechnology company, as the human resources director, responsible for the management, development and organisation of its human resources function.
Cynthia Giuliani received her BA Honours degree from the University of the Witwatersrand in South Africa.

 

 

Marco Manoni
Safety and Facility 

Marco Manoni joined MolMed as Director of Operations in September 2011 and is Facility Planning & Design Director since March 2013. He has more than 20 years experience in research, development, production and quality management  of  chemicals and  biologicals, diagnostics, nutraceuticals, pharmaceutical intermediates, active pharmaceutical ingredients (API) and investigational medicinal products (IMP). Before joining Molmed, he was  a member of the Board of Directors and the Chief Operating Officer at  RSM SpA, aR&D Company focused on development and production of intermediates, active pharmaceutical ingredients and investigational medicinal products, as well as Scientific Director of the Chemical-Pharmaceutical group INALCO, for 11 years. Previously, he was inter alia Development and Operation Manager  at PRIMM, one of the oldest Italian biotech companies.
Marco Manoni holds a Degree in Biology and a Master in Industrial Biotechnology from the State University of Milan.

 

Andrea Quaglino
Administration, Finance & Control Director

Andrea Quaglino joins MolMed in August 2013 as Director Administration Finance &Control. He brings over 13 years auditing experience gained in a Big Four where he held positions of increasing responsibility. He carried out his activity mainly in Italian Groups with foreign subsidiaries operating in the pharmaceutical and luxury retail fields. He was also involved in  important IPO and private placement projects.
Andrea Quaglino  obtained his degree in Economics and Business Administration from the Catholic University in Milan and  is a Chartered Accountant and a registered Public Auditor.

 

Laura Villa
Investor Relations & Communication

Laura Villa joined MolMed as Investor Relations Director in September 2015. She has over 10 years’ experience in financial communication and management of relations with the financial community and relevant regulatory authorities (Borsa Italiana and Consob), gained at Italian and multinational companies of the biomedical and biotechnology sectors (Sorin S.p.A., DiaSorin S.p.A., CTI BioPharma Corp.).
Prior to her roles in Investor Relations she worked for over 5 years in Generali AM in asset and portfolio allocation related functions, responsible for management of global lifescience sector specialized funds. Laura Villa holds a degree in Economics of Public Administrations and International Institutions from the Università Commerciale L. Bocconi in Milan.

 

Tiziano Andreoli
Information Technology 

Tiziano Andreoli is Information Technology Director since January 2016. He joined MolMed in 2011 and he’s always worked in IT groups in different roles with growing responsibilities, focusing his activities in governance and assessments, process and data flows, reverse engineering, software analysis, re-engineering and development. Tiziano holds a degree in Electronic Engineering from Università degli Studi in Brescia.

 

Antonio Lambiase MD
Clinical Development 

Antonio Lambiase joined MolMed in March 2007. He previously worked for over fifteen years at Roche in the areas of oncology and haematology as medical responsible for clinical development of several biological and molecular targeted compounds, including cancer biotherapeutics, haematopoietic growth factors, therapeutic monoclonal antibodies and antiangiogenesis agents. Before that, he spent three years as a research fellow at the Medical Oncology Unit of National Cancer Institute of Milan.
Antonio Lambiase received his degree in Medicine from University of Naples, where he completed his postgraduate studies and specialisation.

 

Catia Traversari
Research 

Catia Traversari joined MolMed in January 2002. Prior to this date, she held the position of head of Cancer Immunotherapy and Gene Therapy in Genera Spa. She has over 15 years experience in tumor immunology and immunotherapy research.
Catia was directly involved in the molecular cloning of the first human tumor antigen gene during her stage at the Ludwig Institute. She is the author of more than 70 publications and inventor of several of the company's core technologies. She joined the San Raffaele Scientific Institute in 1991 and was among the founding members of the Gene Therapy Programme. Previously, Catia Traversari served as Visiting Scientist at the Ludwig Institute for Cancer Research in Bruxelles and as research associate at the Istituto dei Tumori in Milan, one of the leading non-profit cancer research centres in Italy.
Catia Traversari graduated in Biology at the University of Milan.

MolMed S.p.A. Via Olgettina, 58 - 20132 Milano, Italy | Phone +39 0221277.1 - Fax +39 02 21277.325 | info@molmed.com - www.molmed.com
Share capital € 20,312,682.30 fully paid - Office of Milan Company Registry number 1506630 - Tax identification number 11887610159